Breaking News

Wednesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
G1 Therapeutics price target lowered to $50 from $55 at Wedbush » 08:45
07/01/20
07/01
08:45
07/01/20
08:45
GTHX

G1 Therapeutics

$24.27 /

+0.09 (+0.37%)

Wedbush analyst David…

Wedbush analyst David Nierengarten lowered the firm's price target on G1 Therapeutics to $50 from $55 and keeps an Outperform rating on the shares. The analyst notes that the company entered into a co-promotion agreement with Boehringer Ingelheim for trila in small cell lung cancer in the U.S. and Puerto Rico and completed the NDA submission. A commercial partner for trila was long-awaited and Nierengarten views the agreement with BI as a win for G1 Therapeutics, which should facilitate a successful initial launch for trila in SCLC pending a likely approval next year. Appreciably, the agreement with BI leaves the door open for additional commercial partnership opportunities down the road likely to time around topline trila readouts of the Phase 2 I-SPY2 trial in breast cancer and Phase 3 trial in colorectal cancer, he adds. The analyst notes that thanges in his price target are due in part to pushing out the expected launch for trila ex-U.S. and the partnership with BI not being a more traditional pharma license where G1 would receive upfront payments and downstream royalties.

ShowHide Related Items >><<
GTHX G1 Therapeutics
$24.27 /

+0.09 (+0.37%)

GTHX G1 Therapeutics
$24.27 /

+0.09 (+0.37%)

06/26/20 Roth Capital
G1 Therapeutics initiated with a Buy at Roth Capital
05/27/20 JonesTrading
JonesTrading sees potential positive myelopreservation data in June for Aileron
02/27/20 Wedbush
G1 Therapeutics price target lowered to $55 from $67 at Wedbush
01/21/20 H.C. Wainwright
G1 Therapeutics price target raised to $82 from $72 at H.C. Wainwright
GTHX G1 Therapeutics
$24.27 /

+0.09 (+0.37%)

Tuesday
Hot Stocks
G1 Therapeutics, Boehringer announce co-promotion agreement for trilaciclib » 16:17
06/30/20
06/30
16:17
06/30/20
16:17
GTHX

G1 Therapeutics

$24.27 /

+0.09 (+0.37%)

G1 Therapeutics and…

G1 Therapeutics and Boehringer Ingelheim announced that the companies have entered into a co-promotion agreement for trilaciclib in the United States and Puerto Rico. Under the terms of the three-year agreement, G1 and Boehringer Ingelheim will collaborate on the commercialization of trilaciclib for its first potential indication in small cell lung cancer, or SCLC, with the Boehringer Ingelheim oncology commercial team. Discovered and developed by G1, trilaciclib is an investigational therapy designed to improve outcomes for people with cancer treated with chemotherapy. Under the terms of the agreement, G1 will book revenue in the United States and Puerto Rico and retain global development and commercialization rights to trilaciclib. In the U.S. and Puerto Rico, G1 will lead marketing, market access and medical engagement initiatives; Boehringer Ingelheim will lead sales force engagements. G1 will make initial payments to Boehringer Ingelheim to cover start-up expenses and pre-approval initiatives to support a successful commercial launch. G1 will pay a promotion fee of a mid-twenties percentage of net sales in the first year of commercialization, which decreases to a low double-digit/high single-digit percentage in the second and third years of commercialization, respectively. There are no payments due by either party beyond the expiration of the three-year term of the agreement. The agreement does not extend to additional indications that G1 may pursue for trilaciclib.

ShowHide Related Items >><<
GTHX G1 Therapeutics
$24.27 /

+0.09 (+0.37%)

GTHX G1 Therapeutics
$24.27 /

+0.09 (+0.37%)

06/26/20 Roth Capital
G1 Therapeutics initiated with a Buy at Roth Capital
05/27/20 JonesTrading
JonesTrading sees potential positive myelopreservation data in June for Aileron
02/27/20 Wedbush
G1 Therapeutics price target lowered to $55 from $67 at Wedbush
01/21/20 H.C. Wainwright
G1 Therapeutics price target raised to $82 from $72 at H.C. Wainwright
GTHX G1 Therapeutics
$24.27 /

+0.09 (+0.37%)

Over a week ago
Initiation
G1 Therapeutics initiated with a Buy at Roth Capital » 09:14
06/26/20
06/26
09:14
06/26/20
09:14
GTHX

G1 Therapeutics

$24.37 /

+1.22 (+5.27%)

Roth Capital analyst Tony…

Roth Capital analyst Tony Butler initiated coverage of G1 Therapeutics with a Buy rating and $55 price target. The company expects to complete filing an NDA for lead drug, trilaciclib, in small-cell lung cancer by Q2 for a 2021 U.S. launch while it is also developing rintodestrant for ER+/HER2- breast cancer, noted Butler.

ShowHide Related Items >><<
GTHX G1 Therapeutics
$24.37 /

+1.22 (+5.27%)

GTHX G1 Therapeutics
$24.37 /

+1.22 (+5.27%)

05/27/20 JonesTrading
JonesTrading sees potential positive myelopreservation data in June for Aileron
02/27/20 Wedbush
G1 Therapeutics price target lowered to $55 from $67 at Wedbush
01/21/20 H.C. Wainwright
G1 Therapeutics price target raised to $82 from $72 at H.C. Wainwright
01/07/20 BTIG
G1 Therapeutics price target lowered to $51 from $80 at BTIG
GTHX G1 Therapeutics
$24.37 /

+1.22 (+5.27%)

Hot Stocks
G1 Therapeutics, Genor Biopharma announce license agreement for lerociclib » 06:09
06/22/20
06/22
06:09
06/22/20
06:09
GTHX

G1 Therapeutics

$23.63 /

+1.69 (+7.70%)

G1 Therapeutics and Genor…

G1 Therapeutics and Genor Biopharma Co. announced an exclusive license agreement for the development and commercialization of lerociclib in the Asia-Pacific region (excluding Japan). Under the terms of the agreement, G1 will receive an upfront cash payment of $6M and be eligible to receive up to an additional $40M in development and commercial milestone payments. In addition, Genor will pay G1 tiered royalties ranging from high single to low double-digits based on annual net sales of lerociclib. Genor will have exclusive development and commercialization rights for lerociclib in the Asia-Pacific region (excluding Japan).

ShowHide Related Items >><<
GTHX G1 Therapeutics
$23.63 /

+1.69 (+7.70%)

GTHX G1 Therapeutics
$23.63 /

+1.69 (+7.70%)

05/27/20 JonesTrading
JonesTrading sees potential positive myelopreservation data in June for Aileron
02/27/20 Wedbush
G1 Therapeutics price target lowered to $55 from $67 at Wedbush
01/21/20 H.C. Wainwright
G1 Therapeutics price target raised to $82 from $72 at H.C. Wainwright
01/07/20 BTIG
G1 Therapeutics price target lowered to $51 from $80 at BTIG
GTHX G1 Therapeutics
$23.63 /

+1.69 (+7.70%)

Over a month ago
Conference/Events
G1 Therapeutics participates in a conference call with JPMorgan » 10:46
06/02/20
06/02
10:46
06/02/20
10:46
GTHX

G1 Therapeutics

$18.24 /

+0.62 (+3.52%)

JPMorgan SMid Cap Biotech…

JPMorgan SMid Cap Biotech Analyst Rama, along with CEO Velleca and CMO Malik, provides perspectives on Trilaciclib and broader pipeline post-ASCO's recently-held Annual Virtual Meeting on a conference call to be held on June 2 at 12 pm hosted by JPMorgan.

ShowHide Related Items >><<
GTHX G1 Therapeutics
$18.24 /

+0.62 (+3.52%)

GTHX G1 Therapeutics
$18.24 /

+0.62 (+3.52%)

05/27/20 JonesTrading
JonesTrading sees potential positive myelopreservation data in June for Aileron
02/27/20 Wedbush
G1 Therapeutics price target lowered to $55 from $67 at Wedbush
01/21/20 H.C. Wainwright
G1 Therapeutics price target raised to $82 from $72 at H.C. Wainwright
01/07/20 BTIG
G1 Therapeutics price target lowered to $51 from $80 at BTIG
GTHX G1 Therapeutics
$18.24 /

+0.62 (+3.52%)

Recommendations
JonesTrading sees potential positive myelopreservation data in June for Aileron » 11:47
05/27/20
05/27
11:47
05/27/20
11:47
ALRN

Aileron Therapeutics

$0.95 /

+0.0391 (+4.30%)

, GTHX

G1 Therapeutics

$17.62 /

-0.93 (-5.01%)

JonesTrading analyst…

JonesTrading analyst Soumit Roy reiterates a Buy rating and a $5 price target on Aileron Therapeutics (ALRN) after the company guided for early myelopreservation data in June. He expects to see positive data from 11 patients in TP53 mutant 2L SCLC when treated with topotecan, and could see a 50% reduction in the rates of severe anemia and thrombocytopenia, which would be markedly better than peer G1 Therapeutics (GTHX) showing 24% reduction in anemia and 0% reduction in thrombocytopenia. Enrollment has initiated in dose expansion to enroll eight patients and complete data to be presented in Q4, Roy adds.

ShowHide Related Items >><<
GTHX G1 Therapeutics
$17.62 /

-0.93 (-5.01%)

ALRN Aileron Therapeutics
$0.95 /

+0.0391 (+4.30%)

ALRN Aileron Therapeutics
$0.95 /

+0.0391 (+4.30%)

04/08/20 JonesTrading
Aileron Therapeutics initiated with a Buy at JonesTrading
04/08/20 JonesTrading
Aileron Therapeutics initiated with a Buy at JonesTrading
03/31/20 H.C. Wainwright
Aileron Therapeutics price target lowered to $3 from $6 at H.C. Wainwright
GTHX G1 Therapeutics
$17.62 /

-0.93 (-5.01%)

02/27/20 Wedbush
G1 Therapeutics price target lowered to $55 from $67 at Wedbush
01/21/20 H.C. Wainwright
G1 Therapeutics price target raised to $82 from $72 at H.C. Wainwright
01/07/20 BTIG
G1 Therapeutics price target lowered to $51 from $80 at BTIG
08/08/19 JPMorgan
G1 Therapeutics upgraded to Overweight from Neutral at JPMorgan
GTHX G1 Therapeutics
$17.62 /

-0.93 (-5.01%)

ALRN Aileron Therapeutics
$0.95 /

+0.0391 (+4.30%)

Hot Stocks
G1 Therapeutics to present data showing benefits of Trilaciclib in SCLC » 17:32
05/13/20
05/13
17:32
05/13/20
17:32
GTHX

G1 Therapeutics

$15.70 /

+0.06 (+0.38%)

G1 Therapeutics announced…

G1 Therapeutics announced that data across three randomized, double-blind, placebo-controlled Phase 2 trials of the investigational therapy trilaciclib in small cell lung cancer will be presented on May 29 at the ASCO20 Virtual Scientific Program of the American Society of Clinical Oncology. In these trials, trilaciclib was administered prior to chemotherapy treatment and significantly reduced rates of myelosuppression and the need for related supportive care interventions compared with patients receiving chemotherapy treatment alone. In addition, two abstracts on the real-world burden of chemotherapy-induced myelosuppression will be published. Myelosuppression is the result of damage to bone marrow cells, and is one of the most common side effects of chemotherapy. Myelosuppression often requires the administration of rescue interventions such as growth factors and blood or platelet transfusions, and may also result in chemotherapy dose delays and reductions. Immune cell damage may decrease the ability of the immune system to fight the cancer, as well as infection. Trilaciclib is a first-in-class investigational therapy designed to preserve bone marrow and immune system function during chemotherapy and improve patient outcomes. The company plans to complete an NDA submission for trilaciclib for myelopreservation in SCLC in 2Q20. Trilaciclib has been assigned Breakthrough Therapy Designation by the FDA.

ShowHide Related Items >><<
GTHX G1 Therapeutics
$15.70 /

+0.06 (+0.38%)

GTHX G1 Therapeutics
$15.70 /

+0.06 (+0.38%)

02/27/20 Wedbush
G1 Therapeutics price target lowered to $55 from $67 at Wedbush
01/21/20 H.C. Wainwright
G1 Therapeutics price target raised to $82 from $72 at H.C. Wainwright
01/07/20 BTIG
G1 Therapeutics price target lowered to $51 from $80 at BTIG
08/08/19 JPMorgan
G1 Therapeutics upgraded to Overweight from Neutral at JPMorgan
GTHX G1 Therapeutics
$15.70 /

+0.06 (+0.38%)

Earnings
G1 Therapeutics reports Q1 EPS (82c), consensus (98c) » 16:10
05/06/20
05/06
16:10
05/06/20
16:10
GTHX

G1 Therapeutics

$13.96 /

-0.34 (-2.38%)

We have activated…

We have activated business continuity plans in response to the COVID-19 pandemic to ensure we can advance therapies that patients with cancer, their families, and healthcare providers are counting on to improve outcomes, and also taken actions to safeguard the well-being of our employees," said Mark Velleca, M.D., Ph.D., Chief Executive Officer. "We are on track to complete a New Drug Application filing for trilaciclib for patients with small cell lung cancer this quarter, and have initiated virtual medical education programs as we prepare for commercial launch in the U.S. We remain committed to evaluating the benefits of trilaciclib in other indications and expect to initiate the I SPY-2 breast cancer trial this quarter and a pivotal trial in colorectal cancer in the fourth quarter of 2020. Cancer patients experiencing chemotherapy-induced myelosuppression are an especially vulnerable population, and trilaciclib has the potential to be the first proactively administered myelopreservation therapy for these patients." Cash and cash equivalents totaled $242.4 million as of March 31, 2020, compared to $269.2 million as of December 31, 2019.

ShowHide Related Items >><<
GTHX G1 Therapeutics
$13.96 /

-0.34 (-2.38%)

02/27/20 Wedbush
G1 Therapeutics price target lowered to $55 from $67 at Wedbush
01/21/20 H.C. Wainwright
G1 Therapeutics price target raised to $82 from $72 at H.C. Wainwright
01/07/20 BTIG
G1 Therapeutics price target lowered to $51 from $80 at BTIG
08/08/19 JPMorgan
G1 Therapeutics upgraded to Overweight from Neutral at JPMorgan
Conference/Events
Eyeforpharma to hold a virtual conference » 07:53
04/15/20
04/15
07:53
04/15/20
07:53
ABBV

AbbVie

$82.12 /

+4.07 (+5.21%)

, ABEO

Abeona Therapeutics

$2.59 /

+0.175 (+7.25%)

, ALKS

Alkermes

$15.55 /

+0.17 (+1.11%)

, AMGN

Amgen

$226.75 /

+8.46 (+3.88%)

, AMRN

Amarin

$6.38 /

+ (+0.00%)

, AZN

AstraZeneca

$48.71 /

+1.29 (+2.72%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

, BIIB

Biogen

$333.55 /

+10.7 (+3.31%)

, CRM

Salesforce

$157.79 /

+5.27 (+3.46%)

, DIS

Disney

$106.00 /

+2.45 (+2.37%)

, ESALY

Eisai

$0.00 /

+ (+0.00%)

, FB

Facebook

$177.92 /

+3.05 (+1.74%)

, GSK

GlaxoSmithKline

$40.38 /

+1.45 (+3.72%)

, GTHX

G1 Therapeutics

$13.08 /

+0.75 (+6.08%)

, LLY

Eli Lilly

$151.17 /

+6.81 (+4.72%)

, MNK

Mallinckrodt

$3.92 /

+0.175 (+4.67%)

, MRK

Merck

$82.86 /

+2.33 (+2.89%)

, MSFT

Microsoft

$173.70 /

+8.19 (+4.95%)

, NVO

Novo Nordisk

$59.81 /

+1.03 (+1.75%)

, NVS

Novartis

$86.25 /

+2.03 (+2.41%)

, OTSKY

Otsuka

$0.00 /

+ (+0.00%)

, PFE

Pfizer

$36.44 /

+1.29 (+3.67%)

, SEPR

Sepracor

$0.00 /

+ (+0.00%)

, SGEN

Seattle Genetics

$123.79 /

+3.77 (+3.14%)

, SNY

Sanofi

$45.96 /

+1.57 (+3.54%)

, SYNH

Syneos Health

$49.67 /

+2.12 (+4.46%)

, TAK

Takeda Pharmaceutical

$16.88 /

+0.18 (+1.08%)

Eyeforpharma Philadelphia…

Eyeforpharma Philadelphia will be held virtually on April 14-17 with webcasts starting at 9 am each day. Webcast Link

ShowHide Related Items >><<
ABBV AbbVie
$82.12 /

+4.07 (+5.21%)

03/30/20 Piper Sandler
CytomX Therapeutics payment for CX-2029 notable milestone, says Piper Sandler
03/26/20 Piper Sandler
Doctor survey shows 'massive' near-term COVID disruption, says Piper Sandler
03/24/20 Wedbush
CytomX Therapeutics upgraded to Outperform at Wedbush
03/23/20 Societe Generale
AbbVie downgraded to Hold from Buy at Societe Generale
ABEO Abeona Therapeutics
$2.59 /

+0.175 (+7.25%)

12/30/19 H.C. Wainwright
Abeona Therapeutics price target lowered to $11 from $15 at H.C. Wainwright
12/20/19 Cantor Fitzgerald
Abeona financing to lessen takeover chartter, says Cantor Fitzgerald
12/10/19 Cantor Fitzgerald
Abeona Therapeutics assumed with a Neutral at Cantor Fitzgerald
08/15/19
Fly Intel: Top five analyst downgrades
ALKS Alkermes
$15.55 /

+0.17 (+1.11%)

02/14/20 JPMorgan
JPMorgan downgrades Alkermes to Neutral into 'relatively quiet' 2020
02/14/20 H.C. Wainwright
Alkermes profitability focus 'underwhelms' for 2020, says H.C. Wainwright
02/14/20 BofA
Alkermes downgraded to Neutral from Buy at BofA
02/14/20 BofA
Alkermes downgraded to Neutral from Buy at BofA
AMGN Amgen
$226.75 /

+8.46 (+3.88%)

04/13/20 Citi
Sharp drop in chemo use negative for Amgen and Coherus, says Citi
03/31/20 Wolfe Research
Amgen initiated with a Peer Perform at Wolfe Research
03/30/20
Fly Intel: Top five analyst upgrades
03/29/20 Raymond James
Raymond James upgrades Amgen to Outperform on limited COVID-19 disruption
AMRN Amarin
$6.38 /

+ (+0.00%)

04/14/20 Roth Capital
Amarin gearing up to push back against ANDA filers ruling, says Roth Capital
04/14/20 Cowen
Amarin price target raised to $10 from $8 at Cowen
04/14/20 Stifel
Amarin 2020 view 'sufficiently conservative' to still be achievable, says Stifel
04/14/20 Jefferies
Amarin's Vascepa launch continues to be one of best in biotech, says Jefferies
AZN AstraZeneca
$48.71 /

+1.29 (+2.72%)

04/13/20 B. Riley FBR
AstraZeneca study halt has positive read-through to Fortress, says B. Riley FBR
02/28/20 Cowen
AstaZeneca pipeline leads to best European idea, says Cowen
01/27/20 William Blair
PhaseBio could see increase to PB2452 addressable market, says William Blair
01/22/20 Liberum
Sanofi downgraded to Hold from Buy at Liberum (earlier)
BAYRY Bayer
$0.00 /

+ (+0.00%)

03/13/20 Goldman Sachs
Bayer price target lowered to EUR 76 from EUR 77 at Goldman Sachs
03/11/20 Deutsche Bank
Deutsche Bank names Bayer as 'Catalyst Call' buy idea
03/04/20 Deutsche Bank
Bayer upgraded to Buy from Hold at Deutsche Bank
12/19/19 BofA
Elanco upgraded to Buy from Neutral at BofA/Merrill
BIIB Biogen
$333.55 /

+10.7 (+3.31%)

03/31/20 Wolfe Research
Biogen initiated with a Peer Perform at Wolfe Research
03/13/20 Jefferies
Large-cap biotech remains good 'defensive zone' for 2020, says Jefferies
02/28/20 William Blair
Biogen deal with Sangamo unlikely to have near-term impact, says William Blair
CRM Salesforce
$157.79 /

+5.27 (+3.46%)

04/01/20 Wedbush
Salesforce removed from Best Ideas List at Wedbush
03/24/20 Wedbush
Microsoft, Alphabet among stocks in Wedbush's Shopping List
03/20/20 Cowen
Salesforce reiterated as a Best idea at Cowen
02/27/20 RBC Capital
Former Salesforce co-CEO Block could end up at Workday, Oracle, says RBC Capital
DIS Disney
$106.00 /

+2.45 (+2.37%)

04/14/20 SunTrust
Roku price target lowered to $110 from $160 at SunTrust
04/14/20 Credit Suisse
Cogent price target raised to $99 from $86 at Credit Suisse
04/13/20 Cowen
Glu Mobile weakness a buying opportunity, says Cowen
04/09/20 Rosenblatt
Disney+ could reach almost 70M subscribers by end of June, says Rosenblatt
ESALY Eisai
$0.00 /

+ (+0.00%)

10/24/19 Nomura Instinet
Eisai upgraded to Buy from Neutral at Nomura Instinet
09/24/19 Jefferies
Eisai initiated with a Buy at Jefferies
09/17/19 Daiwa
Eisai downgraded to Sell from Neutral at Daiwa
08/05/19 Citi
Eisai upgraded to Neutral from Sell at Citi
FB Facebook
$177.92 /

+3.05 (+1.74%)

04/09/20 Loop Capital
Facebook price target lowered to $215 from $245 at Loop Capital
04/08/20 Deutsche Bank
Pinterest update shows Snap could post in-line Q1, says Deutsche Bank
04/07/20 Barclays
Facebook price target lowered to $175 from $260 at Barclays
04/02/20 Rosenblatt
Rosenblatt cuts advertising estimates, says Facebook/Roku/Snap show best upside
GSK GlaxoSmithKline
$40.38 /

+1.45 (+3.72%)

03/11/20 JPMorgan
JPMorgan backs Neutral on GSK after 2019 annual report
01/16/20 Barclays
GlaxoSmithKline downgraded to Underweight from Equal Weight at Barclays
12/16/19 Goldman Sachs
BioMarin, Regeneron among Goldman's six Healthcare 'laggards' for 2020
12/03/19 Morgan Stanley
Morgan Stanley sees high odds of Bluebird trading up after multiple myeloma data
GTHX G1 Therapeutics
$13.08 /

+0.75 (+6.08%)

02/27/20 Wedbush
G1 Therapeutics price target lowered to $55 from $67 at Wedbush
01/21/20 H.C. Wainwright
G1 Therapeutics price target raised to $82 from $72 at H.C. Wainwright
01/07/20 BTIG
G1 Therapeutics price target lowered to $51 from $80 at BTIG
08/08/19 JPMorgan
G1 Therapeutics upgraded to Overweight from Neutral at JPMorgan
LLY Eli Lilly
$151.17 /

+6.81 (+4.72%)

04/09/20 Morgan Stanley
Morgan Stanley downgrades Eli Lilly to Equal Weight with premium near prior peak
04/09/20 Morgan Stanley
Eli Lilly downgraded to Equal Weight from Overweight at Morgan Stanley
03/11/20
Fly Intel: Top five analyst upgrades
03/11/20 Goldman Sachs
Eli Lilly upgraded to Conviction Buy from Buy at Goldman Sachs
MNK Mallinckrodt
$3.92 /

+0.175 (+4.67%)

02/25/20 Stifel
Mallinckrodt clearing path for shares to be revalued, says Stifel
01/22/20 Wells Fargo
Revance, Amphastar named top 2020 Specialty Pharmaceuticals ideas at Wells Fargo
09/10/19 Stifel
Mallinckrodt's sale of BioVectra helps alleviate cash pressure, says Stifel
09/09/19 Stifel
Mallinckrodt price target lowered to $8 from $20 at Stifel
MRK Merck
$82.86 /

+2.33 (+2.89%)

04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
03/23/20 Mizuho
Merck business disruptions have been modest, says Mizuho
03/02/20 William Blair
Merck results revive fears about Seattle Genetics' Adcetris, says William Blair
02/27/20 Barclays
Merck initiated with an Overweight at Barclays
MSFT Microsoft
$173.70 /

+8.19 (+4.95%)

04/15/20 BofA
Microsoft estimates trimmed after reseller checks at BofA
04/02/20 Piper Sandler
RingCentral videoconference product launch negative for Zoom, says Piper Sandler
03/31/20 Citi
Microsoft price target lowered to $167 from $170 at Citi
03/26/20 Baird
Bandwidth added as a Fresh Pick at Baird
NVO Novo Nordisk
$59.81 /

+1.03 (+1.75%)

03/23/20 UBS
Novo Nordisk upgraded to Buy from Neutral at UBS
03/16/20 BofA
Novo Nordisk upgraded to Buy from Neutral at BofA
01/03/20 Guggenheim
Novo Nordisk downgraded to Neutral on continued insulin headwinds at Guggenheim
01/03/20 Guggenheim
Novo Nordisk downgraded to Neutral from Buy at Guggenheim
NVS Novartis
$86.25 /

+2.03 (+2.41%)

03/26/20 Argus
Alcon upgraded to Buy from Hold at Argus
03/11/20 Morgan Stanley
Novartis upgraded to Equal Weight yesterday at Morgan Stanley
03/10/20 H.C. Wainwright
Novartis' recent R&D day driving interest in Xoma, says H.C. Wainwright
03/10/20 Morgan Stanley
Novartis upgraded to Equal Weight from Underweight at Morgan Stanley
OTSKY Otsuka
$0.00 /

+ (+0.00%)

03/26/20 Citi
Otsuka upgraded to Buy from Neutral at Citi
03/24/20 JPMorgan
Otsuka upgraded to Neutral from Underweight at JPMorgan
12/26/19 Mizuho
Otsuka downgraded to Neutral from Buy at Mizuho
12/09/19 Jefferies
Otsuka initiated with a Buy at Jefferies
PFE Pfizer
$36.44 /

+1.29 (+3.67%)

04/03/20 Canaccord
BioNTech price target raised to $60 from $22 at Canaccord
03/25/20 Piper Sandler
Piper Sandler sees FY20 U.S. sales of Opko's Rayaldee at $52.5M
02/27/20 Standpoint Research
Pfizer upgraded to Buy from Hold at Standpoint Research
02/27/20 Barclays
Pfizer initiated with an Equal Weight at Barclays
SEPR Sepracor
$0.00 /

+ (+0.00%)

SGEN Seattle Genetics
$123.79 /

+3.77 (+3.14%)

04/03/20 Stifel
Stifel says Seattle Genetics FDA talks on EV positive, but not surprising
02/18/20 Barclays
Seattle Genetics downgraded to Equal Weight from Overweight at Barclays
02/18/20 Barclays
Seattle Genetics downgraded to Equal Weight from Overweight at Barclays
SNY Sanofi
$45.96 /

+1.57 (+3.54%)

03/27/20 Roth Capital
Roth Capital highlights Translate Bio's scalable mRNA platform
03/17/20 Barclays
Sanofi upgraded to Equal Weight from Underweight at Barclays
03/11/20 Oppenheimer
Regeneron price target raised to $525 from $450 at Oppenheimer
03/10/20 Goldman Sachs
Sanofi upgraded to Buy from Neutral at Goldman Sachs
SYNH Syneos Health
$49.67 /

+2.12 (+4.46%)

04/03/20 Mizuho
Syneos Health price target lowered to $42 from $56 at Mizuho
04/02/20 Credit Suisse
Syneos Health price target lowered to $62 from $72 at Credit Suisse
03/30/20 Goldman Sachs
Syneos Health downgraded to Neutral from Buy at Goldman Sachs
03/17/20 SunTrust
SunTrust cuts price targets across CROs, downgrades MedPace
TAK Takeda Pharmaceutical
$16.88 /

+0.18 (+1.08%)

03/25/20 Piper Sandler
Piper Sandler backs Overweight on 'well capitalized' Exelixis
03/25/20 Stifel
Molecular Templates initiated with a Buy at Stifel
02/25/20 Stifel
Iovance among 'more interesting' cell therapy takeout candidates, says Stifel
02/12/20 Wells Fargo
Fate Therapeutics price target raised to $34 from $24 at Wells Fargo
Over a quarter ago
Hot Stocks
NextCure appoints Garry Nicholson to board of directors » 07:43
03/30/20
03/30
07:43
03/30/20
07:43
NXTC

NextCure

$36.65 /

-1.17 (-3.09%)

, GTHX

G1 Therapeutics

$11.28 /

-0.71 (-5.92%)

NextCure (NXTC) announced…

NextCure (NXTC) announced the appointment of Garry Nicholson to its board of directors. In addition, Timothy M. Shannon, M.D. notified NextCure that he is stepping down from the company's board of directors. Nicholson currently serves as chairman of the board for G1 Therapeutics (GTHX) and as a board member for Turning Point Therapeutics, Five Prime Therapeutics, Personal Genome Diagnostics and Tmunity Therapeutics.

ShowHide Related Items >><<
NXTC NextCure
$36.65 /

-1.17 (-3.09%)

03/24/20 Benchmark
NextCure initiated with a Buy at Benchmark
03/02/20 Roth Capital
NextCure initiated with a Buy at Roth Capital
01/13/20 Piper Sandler
Partnership termination not a negative for NextCure N318, says Piper Sandler
01/13/20 SunTrust
NextCure initiated with a Buy at SunTrust
GTHX G1 Therapeutics
$11.28 /

-0.71 (-5.92%)

02/27/20 Wedbush
G1 Therapeutics price target lowered to $55 from $67 at Wedbush
01/21/20 H.C. Wainwright
G1 Therapeutics price target raised to $82 from $72 at H.C. Wainwright
01/07/20 BTIG
G1 Therapeutics price target lowered to $51 from $80 at BTIG
08/08/19 JPMorgan
G1 Therapeutics upgraded to Overweight from Neutral at JPMorgan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.